Open Access

CD271+ stem cell treatment of patients with chronic stroke

  • Authors:
    • Felician Stancioiu
    • Georgios Z. Papadakis
    • George Lazopoulos
    • Demetrios A. Spandidos
    • Aristidis Tsatsakis
    • Marius Floroiu
    • Corin Badiu
  • View Affiliations

  • Published online on: June 26, 2020     https://doi.org/10.3892/etm.2020.8948
  • Pages: 2055-2062
  • Copyright: © Stancioiu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Patients with chronic stroke have currently little hope for motor improvement towards regaining independent activities of daily living; stem cell treatments offer a new treatment option and needs to be developed. Patients with chronic stroke (more than 3 months prior to stem cell treatment, mean 21.2 months post‑stroke) were treated with CD271+ stem cells, 7 patients received autologous and 1 allogeneic cells from first degree relative; administration was intravenous in 1 and intrathecal in 7 patients. Each patient received a single treatment consisting of 2‑5x106 cells/kg and they were followed up for up to 12 months. There were significant improvements in expressive aphasia (2/3 patients) spasticity (5/5, of which 2 were transient), and small improvements in motor function (2/8 patients). Although motor improvements were minor in our chronic stroke patients, improvements in aphasia and spasticity were significant and in the context of good safety we are advocating further administration and clinical studies of CD271+ stem cells not only in chronic stroke patients, but also for spastic paresis/plegia; a different, yet unexplored application is pulmonary emphysema.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Stancioiu F, Papadakis GZ, Lazopoulos G, Spandidos DA, Tsatsakis A, Floroiu M and Badiu C: CD271+ stem cell treatment of patients with chronic stroke. Exp Ther Med 20: 2055-2062, 2020
APA
Stancioiu, F., Papadakis, G.Z., Lazopoulos, G., Spandidos, D.A., Tsatsakis, A., Floroiu, M., & Badiu, C. (2020). CD271+ stem cell treatment of patients with chronic stroke. Experimental and Therapeutic Medicine, 20, 2055-2062. https://doi.org/10.3892/etm.2020.8948
MLA
Stancioiu, F., Papadakis, G. Z., Lazopoulos, G., Spandidos, D. A., Tsatsakis, A., Floroiu, M., Badiu, C."CD271+ stem cell treatment of patients with chronic stroke". Experimental and Therapeutic Medicine 20.3 (2020): 2055-2062.
Chicago
Stancioiu, F., Papadakis, G. Z., Lazopoulos, G., Spandidos, D. A., Tsatsakis, A., Floroiu, M., Badiu, C."CD271+ stem cell treatment of patients with chronic stroke". Experimental and Therapeutic Medicine 20, no. 3 (2020): 2055-2062. https://doi.org/10.3892/etm.2020.8948